Skip to search formSkip to main contentSkip to account menu

clazosentan

Known as: N-(6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)pyridin-4-yl)pyrimidin-4-yl)-5-methylpyridine-2-sulfonamide, N-{6-(2-Hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)pyridin-4-yl)pyrimidin-4-yl}-5-methylpyridine-2-sulfonamide 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (2)

AXV 034VML-588

Broader (5)

DioxanesPyridinesPyrimidinesSulfonamides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Attributing Hypodensities on CT to Angiographic Vasospasm Is Not Sensitive and Unreliable
Background and Purpose— The presence of low-density areas on CT is used in clinical decision-making regarding treatment of… 
2011
2011
Dissociation of Vasospasm and Secondary Effects of Experimental Subarachnoid Hemorrhage by Clazosentan
Background and Purpose— Endothelin receptor antagonists such as clazosentan decrease large-artery vasospasm after experimental… 
2011
2011
Influence of Severe Renal Impairment on the Pharmacokinetics of Clazosentan
The purpose of this open‐label, parallel‐group study was to investigate the effect of severe renal impairment on the… 
2011
2011
Retracted Article: Clazosentan, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain injury
OBJECTIVES The purpose of this study was to test the efficacy of a novel endothelin receptor A antagonist on blood flow and… 
2008
2008
Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats.
OBJECT Acute cerebral hypoperfusion and early disturbances in cerebral autoregulation after subarachnoid hemorrhage (SAH) have… 
2007
2007
Effects of the selective endothelin A (ETA) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage – preliminary results from a…
SummaryObjective. To study the effects of clazosentan, a new selective endothelin receptor subtype A antagonist, on cerebral… 
2007
2007
Influence of Ethnic Origin and Sex on the Pharmacokinetics of Clazosentan
This study investigated the influence of ethnic origin and, as a secondary objective, sex on the pharmacokinetics of the… 
2007
2007
Effect of Gender on the Tolerability,Safety and Pharmacokinetics of Clazosentan Following Long-Term Infusion
Objective:The purpose of this study was to investigate the effect of gender on the tolerability, safety and pharmacokinetics of… 
2007
2007
Effect of delayed cerebral vasospasm on cerebrovascular endothelin A receptor expression and function.
OBJECT The key role in the development of cerebral vasospasm after subarachnoid hemorrhage (SAH) is increasingly assigned to… 
2006
2006
Clazosentan (Actelion).
Clazosentan, an endothelin ETA antagonist, is under development by Actelion (formerly Axovan), under license from F Hoffman-La… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)